David E Fuchs, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 3045 Marietta Ave, Lancaster, PA 17601 Phone: 717-898-2900 |
Dr. Nicholas J Dragann Jr., D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1366 Beaconfield Ln, Lancaster, PA 17601 Phone: 717-299-1566 |
Anne-marie Derrico, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 304 N Water St, Lancaster, PA 17603 Phone: 717-299-6371 |
Dr. David Ling, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2145 Noll Dr, Lancaster, PA 17603 Phone: 717-397-4921 Fax: 717-397-7170 |
Samantha E Day, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 555 N Duke St, Fam Med, Lancaster, PA 17602 Phone: 717-544-7228 Fax: 717-544-4149 |
Jean David Dumornay, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 555 North Duke Street, Lancaster, PA 17604 Phone: 717-544-4978 |
News Archive
Advanced metastatic melanoma is a disease that has proven difficult to eradicate. Despite the success of melanoma-targeting drugs, tumors inevitably become drug resistant and return, more aggressive than before. In the current issue of the journal Cancer Cell, however, researchers at The Wistar Institute describe how they increase the effectiveness of anti-melanoma drugs by combining anticancer therapies with diabetes drugs.
Infertile men are at nearly three times greater risk for developing clinically significant prostate cancer than the average man according to a new study published in the journal, Cancer.
Scientists at the Gladstone Institutes and the University of California, San Francisco (UCSF), identified a common mechanism in two forms of neurodegeneration that affect young adults or the elderly.
Lack of the enzyme, acetyl CoA carboxylase 2 or ACC2, appears to turn the adipose or fat cells of mice into fat burners, explaining in part why the animals can eat more and weigh less than their normal counterparts, said Baylor College of Medicine researchers.
AgaMatrix, Inc. and sanofi-aventis today announced that they have signed a long-term agreement for the development, supply and commercialization of blood glucose monitoring (BGM) solutions. Under the terms of the agreement, AgaMatrix and sanofi-aventis will co-develop innovative solutions in diabetes management that incorporate AgaMatrix's WaveSenseâ„¢ technology. Sanofi-aventis will commercialize through its Global Diabetes Division such integrated solutions for patients with diabetes, along with current sanofi-aventis insulins and delivery devices.
› Verified 2 days ago